Oslo, 09 April 2026:
Please find enclosed the 2025 Annual Report for Exact Therapeutics AS.
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com
John M. Edminson
CFO EXACT Therapeutics
Email: john.edminson@exact-tx.com
About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound to activate the proprietary drug PS101 and enhance the
clinical benefit of oncology therapies. PS101 has a unique mode of action and
may be combined with a wide range of therapeutic agents within oncology and
across a multitude of other indications, including brain diseases. EXACT
Therapeutics' shares are traded on Euronext Growth Oslo (EXTX). Further
information may be found here: www.exact-tx.com